Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 2527 | 43.565 |
09:36 ET | 400 | 43.57 |
09:38 ET | 500 | 43.935 |
09:39 ET | 7615 | 44.26 |
09:43 ET | 100 | 44.365 |
09:45 ET | 100 | 44.15 |
09:50 ET | 100 | 44.345 |
09:52 ET | 600 | 44.22 |
09:54 ET | 1300 | 44.14 |
09:56 ET | 1100 | 43.7958 |
09:57 ET | 8049 | 44.025 |
09:59 ET | 300 | 43.98 |
10:01 ET | 5600 | 44.23 |
10:06 ET | 628 | 43.9 |
10:08 ET | 500 | 43.79 |
10:12 ET | 100 | 43.995 |
10:15 ET | 700 | 43.82 |
10:17 ET | 100 | 43.81 |
10:21 ET | 400 | 43.785 |
10:32 ET | 200 | 43.5 |
10:33 ET | 700 | 43.64 |
10:35 ET | 100 | 43.63 |
10:39 ET | 100 | 43.62 |
10:42 ET | 500 | 43.71 |
10:46 ET | 300 | 43.69 |
10:48 ET | 400 | 43.59 |
10:53 ET | 400 | 43.61 |
10:57 ET | 6007 | 43.88 |
11:00 ET | 819 | 43.875 |
11:02 ET | 1533 | 43.89 |
11:04 ET | 200 | 43.82 |
11:08 ET | 700 | 43.86 |
11:09 ET | 3201 | 43.99 |
11:11 ET | 300 | 44 |
11:18 ET | 1928 | 43.9 |
11:20 ET | 2000 | 43.89 |
11:24 ET | 300 | 43.88 |
11:26 ET | 1000 | 43.96 |
11:29 ET | 258 | 43.97 |
11:31 ET | 100 | 43.945 |
11:33 ET | 800 | 43.88 |
11:36 ET | 100 | 43.76 |
11:42 ET | 100 | 43.91 |
11:44 ET | 100 | 43.89 |
11:47 ET | 200 | 43.83 |
11:49 ET | 100 | 43.92 |
11:51 ET | 233 | 43.89 |
11:54 ET | 200 | 43.92 |
11:56 ET | 100 | 44.02 |
11:58 ET | 300 | 43.972 |
12:02 ET | 200 | 43.95 |
12:03 ET | 600 | 43.91 |
12:05 ET | 200 | 43.94 |
12:07 ET | 939 | 43.985 |
12:12 ET | 100 | 44.08 |
12:14 ET | 800 | 44.03 |
12:18 ET | 2866 | 43.92 |
12:23 ET | 525 | 43.64 |
12:25 ET | 100 | 43.7 |
12:36 ET | 400 | 43.7 |
12:38 ET | 100 | 43.84 |
12:39 ET | 400 | 43.57 |
12:41 ET | 115 | 43.7 |
12:43 ET | 1773 | 43.7 |
12:54 ET | 200 | 43.705 |
12:57 ET | 100 | 43.82 |
12:59 ET | 482 | 43.7 |
01:01 ET | 100 | 43.795 |
01:03 ET | 100 | 43.81 |
01:08 ET | 100 | 43.81 |
01:10 ET | 500 | 43.79 |
01:12 ET | 100 | 43.7 |
01:15 ET | 200 | 43.79 |
01:17 ET | 200 | 43.65 |
01:19 ET | 223 | 43.8 |
01:24 ET | 100 | 43.8 |
01:28 ET | 100 | 43.792 |
01:30 ET | 100 | 43.8 |
01:35 ET | 1206 | 43.7 |
01:37 ET | 100 | 43.7 |
01:44 ET | 100 | 43.79 |
01:46 ET | 100 | 43.7 |
01:48 ET | 1482 | 44.03 |
01:51 ET | 100 | 43.99 |
02:04 ET | 111 | 44.03 |
02:06 ET | 153 | 44.04 |
02:11 ET | 100 | 44.042 |
02:13 ET | 448 | 43.91 |
02:15 ET | 303 | 44.04 |
02:18 ET | 132 | 43.95 |
02:20 ET | 900 | 43.94 |
02:22 ET | 800 | 43.86 |
02:26 ET | 200 | 43.93 |
02:29 ET | 400 | 43.84 |
02:33 ET | 200 | 43.835 |
02:36 ET | 700 | 43.88 |
02:38 ET | 4220 | 43.875 |
02:40 ET | 635 | 43.85 |
02:42 ET | 100 | 43.865 |
02:44 ET | 100 | 43.84 |
02:45 ET | 502 | 43.875 |
02:47 ET | 400 | 43.865 |
02:49 ET | 100 | 43.94 |
02:51 ET | 100 | 43.875 |
02:56 ET | 200 | 43.875 |
02:58 ET | 200 | 43.93 |
03:00 ET | 300 | 43.92 |
03:02 ET | 200 | 43.85 |
03:03 ET | 100 | 43.96 |
03:05 ET | 900 | 43.885 |
03:07 ET | 200 | 43.885 |
03:09 ET | 668 | 43.885 |
03:12 ET | 419 | 43.885 |
03:18 ET | 100 | 43.885 |
03:21 ET | 100 | 43.885 |
03:23 ET | 265 | 43.895 |
03:25 ET | 300 | 43.94 |
03:27 ET | 700 | 43.97 |
03:30 ET | 200 | 43.94 |
03:32 ET | 300 | 43.945 |
03:34 ET | 483 | 43.89 |
03:36 ET | 1000 | 43.875 |
03:39 ET | 1059 | 43.85 |
03:41 ET | 400 | 43.93 |
03:43 ET | 200 | 43.915 |
03:45 ET | 1011 | 43.87 |
03:48 ET | 1056 | 43.915 |
03:50 ET | 1000 | 43.945 |
03:52 ET | 4569 | 43.965 |
03:54 ET | 3517 | 43.985 |
03:56 ET | 6910 | 43.99 |
03:57 ET | 4117 | 43.985 |
03:59 ET | 8535 | 43.96 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 3.3B | -16.2x | --- |
Biohaven Ltd | 3.6B | -6.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
IDEAYA Biosciences Inc | 3.5B | -21.2x | --- |
MoonLake Immunotherapeutics | 2.9B | -59.7x | --- |
Apogee Therapeutics Inc | 2.8B | -24.4x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -16.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.